Japan Cell And Gene Therapy Manufacturing Market Size & Outlook
Global Market
Related Markets
Japan cell and gene therapy manufacturing market highlights
- The Japan cell and gene therapy manufacturing market generated a revenue of USD 292.6 million in 2022 and is expected to reach USD 1,913.4 million by 2030.
- The Japan market is expected to grow at a CAGR of 26.5% from 2023 to 2030.
- In terms of segment, cell therapy was the largest revenue generating therapy type in 2022.
- Gene Therapy is the most lucrative therapy type segment registering the fastest growth during the forecast period.
Cell and gene therapy manufacturing market data book summary
| Market revenue in 2022 | USD 292.6 million |
| Market revenue in 2030 | USD 1,913.4 million |
| Growth rate | 26.5% (CAGR from 2023 to 2030) |
| Largest segment | Cell therapy |
| Fastest growing segment | Gene Therapy |
| Historical data | 2018 - 2021 |
| Base year | 2022 |
| Forecast period | 2023 - 2030 |
| Quantitative units | Revenue in USD million |
| Market segmentation | Gene Therapy, Cell Therapy |
| Key market players worldwide | Lonza Group Ltd, Bluebird bio Inc, Catalent Inc, Roche, Samsung BioLogics, Boehringer Ingelheim, Hitachi Ltd, Takara Bio Inc, Miltenyi Biotec, Thermo Fisher Scientific Inc, Novartis AG ADR, Merck KGaA, Wuxi AppTec Co Ltd |
Other key industry trends
- In terms of revenue, Japan accounted for 4.0% of the global cell and gene therapy manufacturing market in 2022.
- Country-wise, U.S. is expected to lead the global market in terms of revenue in 2030.
- In Asia Pacific, China cell and gene therapy manufacturing market is projected to lead the regional market in terms of revenue in 2030.
- China is the fastest growing regional market in Asia Pacific and is projected to reach USD 2,689.5 million by 2030.
Owing to the rising demand for gene therapy products and the presence of enthusiastic investors, the Japanese gene therapy sector is considered as one of the emerging markets in the Asia Pacific region. Takara Bio—a Japan-based company—is a major player in cell and gene therapy manufacturing.
Recently in May 2020, the company expanded its Center for Gene and Cell Processing with the construction of a new facility in Shiga, Japan. This facility is dedicated to the manufacturing of cell and gene therapy products. The presence of such companies with expanding manufacturing services is anticipated to fuel growth of the Japanese market.
In addition, several local companies such as Daiichi Sankyo and Takeda Pharmaceuticals are engaged in capitalizing the avenues by undertaking various initiatives such as partnerships and acquisitions. For instance, in April 2020, Daiichi Sankyo entered into a collaboration with Ultragenyx Pharmaceutical Inc. for the use of gene therapy manufacturing technology.
No credit card required*
Horizon in a snapshot
- 30K+ Global Market Reports
- 120K+ Country Reports
- 1.2M+ Market Statistics
- 200K+ Company Profiles
- Industry insights and more
Three ways to get this data
Subscribe to the databook, customize it, or ask a question.Horizon Databook
Unlock every chart on this page and get dashboard access
- Statistics1.2M+ across all markets
- Databooks30K+ global, 120K+ country
- Companies200K+ profiles
- ExportPDF, Dashboard, XLS & PNG, licensed to cite
Customize it
Customize data as per your requirement
- AddCountries, segments, years
- RecutTo your product definition
- ExtendCompany-level detail
- OrA bespoke databook
- Turnaround5–10 working days
Ask Prism AI
A cited answer in seconds
- Corpus30,000 studies, 1.2M points
- ScopeAll markets, not just this
- CitationTraced to report & table
- HonestySays "not covered" if so
- SpeedSeconds, not days
Cell And Gene Therapy Manufacturing Market Scope
Cell And Gene Therapy Manufacturing Market Companies
| Name | Profile | # Employees | HQ | Website |
|---|---|---|---|---|
| Novartis AG ADR | View profile | 76,057 | Lichtstrasse 35, Basel, Switzerland, 4056 | www.novartis.com |
| Merck KGaA | View profile | 62,345 | Frankfurter Strasse 250, Darmstadt, HE, Germany, 64293 | www.emdgroup.com |
| Hitachi Ltd | View profile | 322,525 | 6-6, Marunouchi 1-chome, Chiyoda-ku, Tokyo, Japan, 100-8280 | www.hitachi.com |
| Lonza Group Ltd | View profile | 18,000 | Muenchensteinerstrasse 38, Basel, Switzerland, CH-4002 | www.lonza.com |
| Thermo Fisher Scientific Inc | View profile | 122,000 | 168 Third Avenue, Waltham, MA, United States, 02451 | www.thermofisher.com |
| Takara Bio Inc | View profile | 1,793 | Nojihigashi 7-4-38 Kusatu, Shiga, Otsu, Japan, 520-0058 | www.takara-bio.co.jp |
| Boehringer Ingelheim | View profile | 10001+ | Ingelheim Am Rhein, Rheinland-Pfalz, Germany, Europe | www.boehringer-ingelheim.com/ |
| Wuxi AppTec Co Ltd | View profile | 41,116 | 288 Fute Zhong Road, Waigaoqiao Free Trade Zone, Shanghai, China, People's Republic of, 200131 | www.wuxiapptec.com |
| Catalent Inc | View profile | 17,219 | 14 Schoolhouse Road, Somerset, NJ, United States, 08873 | www.catalent.com |
| Roche | View profile | 10001+ | Basel, Basel-Stadt, Switzerland, Europe | www.roche.com |
Japan Cell And Gene Therapy Manufacturing Market Outlook
The databook is designed to serve as a comprehensive guide to navigating this sector. The databook focuses on market statistics denoted in the form of revenue and y-o-y growth and CAGR across the globe and regions. A detailed competitive and opportunity analyses related to Cell And Gene Therapy Manufacturing Market Outlook will help companies and investors design strategic landscapes.
Cell Therapy was the largest segment with a revenue share of 57.35% in 2022.
Horizon Databook has segmented the Japan cell and gene therapy manufacturing market based on gene therapy, cell therapy covering the revenue growth of each sub-segment from 2018 to 2030.
Owing to the rising demand for gene therapy products and the presence of enthusiastic investors, the Japanese gene therapy sector is considered as one of the emerging markets in the Asia Pacific region. Takara Bio—a Japan-based company—is a major player in cell and gene therapy manufacturing.
Recently in May 2020, the company expanded its Center for Gene and Cell Processing with the construction of a new facility in Shiga, Japan. This facility is dedicated to the manufacturing of cell and gene therapy products. The presence of such companies with expanding manufacturing services is anticipated to fuel growth of the Japanese market.
In addition, several local companies such as Daiichi Sankyo and Takeda Pharmaceuticals are engaged in capitalizing the avenues by undertaking various initiatives such as partnerships and acquisitions. For instance, in April 2020, Daiichi Sankyo entered into a collaboration with Ultragenyx Pharmaceutical Inc. for the use of gene therapy manufacturing technology.
- Japan Cell And Gene Therapy Manufacturing Market Therapy Type Outlook (Revenue, USD Million , 2018-2030)
- Gene Therapy
- Cell Therapy
- Japan Cell And Gene Therapy Manufacturing Market Scale Outlook (Revenue, USD Million , 2018-2030)
- Pre-commercial/ R&D Scale
- Commercial Scale
- Japan Cell And Gene Therapy Manufacturing Market Mode Outlook (Revenue, USD Million , 2018-2030)
- Contract manufacturing
- In house manufacturing
- Japan Cell And Gene Therapy Manufacturing Market Workflow Outlook (Revenue, USD Million , 2018-2030)
- Cell Processing
- Cell Banking
- Process Development
- Fill & Finish Operations
- Analytical & Quality Testing
- Raw Material Testing
- Vector Production
- Others
- Japan Cell And Gene Therapy Manufacturing Market Indication Outlook (Revenue, USD Million , 2018-2030)
- Acute Lymphoblastic Leukemia (ALL)
- Inherited Retinal Disease
- Malignancies
- Musculoskeletal therapies
- Autoimmune disorders
- Dermatology
- Large B-Cell Lymphoma
- Spinal Muscular Atrophy (SMA)
- Others
Reasons to subscribe to Cell And Gene Therapy Manufacturing Market Outlook databook
- Access to comprehensive data: Horizon Databook provides over 1 million market statistics and 20,000+ reports, offering extensive coverage across various industries and regions.
- Informed decision making: Subscribers gain insights into market trends, customer preferences, and competitor strategies, empowering informed business decisions.
- Cost-Effective solution: It's recognized as the world's most cost-effective market research database, offering high ROI through its vast repository of data and reports.
- Customizable reports: Tailored reports and analytics allow companies to drill down into specific markets, demographics, or product segments, adapting to unique business needs.
- Strategic advantage: By staying updated with the latest market intelligence, companies can stay ahead of competitors, anticipate industry shifts, and capitalize on emerging opportunities.
Target buyers of Cell And Gene Therapy Manufacturing Market Outlook databook
- Our clientele includes a mix of Cell And Gene Therapy Manufacturing Market Outlook companies, investment firms, advisory firms & academic institutions.
- 30% of our revenue is generated working with investment firms and helping them identify viable opportunity areas.
- Approximately 65% of our revenue is generated working with competitive intelligence & market intelligence teams of market participants (manufacturers, service providers, etc.).
- The rest of the revenue is generated working with academic and research not-for-profit institutes. We do our bit of pro-bono by working with these institutions at subsidized rates.
Horizon Databook provides a detailed overview of country-level data and insights on the Japan Cell And Gene Therapy Manufacturing Market Outlook, including forecasts for subscribers. This country databook contains high-level insights into Japan Cell And Gene Therapy Manufacturing Market Outlook from 2018 to 2030, including revenue numbers, major trends, and company profiles.
Japan Cell And Gene Therapy Manufacturing Market, 2018-2030 (US$M)
Japan cell and gene therapy manufacturing market statistics, by therapy type, 2018-2030 (US$M)
